Jeroen J. Lammerts van Bueren

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk, Sandra Verploegen, Marijn Bögels et al. · mAbs · 2015 · 503 citations · Full text

Medicine, Immunology, Oncology +17

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Marije B. Overdijk, J.H. Marco Jansen, Maaike Nederend et al. · The Journal of Immunology · 2016 · 287 citations · Full text

Medicine, Oncology, Pharmacology +16

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

Tanja Schneider‐Merck, Jeroen J. Lammerts van Bueren, Sven Berger et al. · The Journal of Immunology · 2009 · 219 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck et al. · Blood · 2008 · 218 citations · Full text

Pharmacy, Cell Biology, Immunology +17

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Esther Drent, Richard W.J. Groen, Willy A. Noort et al. · Haematologica · 2016 · 200 citations · Full text

Medicine, Immunology, Oncology +17